Tumour necrosis factor inhibitors: Risks and benefits in patients with rheumatoid arthritis

Internal Medicine Journal

Volumn 34, Issue 12, 2004, Pages 687-693

  Roberts, L ^a   McColl, G J ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Adalimumab; Etanercept; Infliximab; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; ANTIBODY; ANTINUCLEAR ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; LENERCEPT; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

ASEPTIC MENINGITIS; AUSTRALIA; CANCER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HEALTH CARE COST; HEART FAILURE; HUMAN; INFECTION COMPLICATION; INJECTION SITE REACTION; LUNG DISEASE; LUNG INFECTION; MENINGITIS; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEPSIS; SEPTICEMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS;

EID: 12344335489     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00710.x     Document Type: Review

References (47)

1. Access Economics. [online] Rheumatoid arthritis: management in adults and juveniles. Report. Canberra: Access Economics; 2002 [cited August 2003]. Available from URL http://www.accesseconomics.com.au
2. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-73.
3. American College of Rheumatology. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46: 328-46.
4. Williamson AA, McColl GJ. Early rheumatoid arthritis: can we predict its outcome? Intern Med J 2001; 31: 168-80.
5. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91.
6. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-25.
7. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
8. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
9. Maini RN, Breeveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH et al Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-65.
10. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein. N Engl J Med 1997; 337: 141-7.
11. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
12. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
13. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004; 363: 675-81.
14. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic frug treatment has failed. Ann Rheum Dis 2004; 63: 508-16.
15. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
16. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheumat 2004; 50: 1400-11.
17. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van't Hof MA, van Rijswijk MH, van de Putte LB. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34.
18. Campbell IK, Roberts LJ, Wicks IP. Molecular targets in immune- mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol Cell Biol 2003; 81: 354-66.
19. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
20. Kavanaugh A, Cush JJ, Matteson E. Hotline: FDA Meeting: Update on the Safety of New Drugs for Rheumatoid Arthritis. Atlanta: American College of Rheumatology; 2003.
21. United States Food and Drug Administration Safety Information and Adverse Event Reporting Program [online]. Safety alert for Remicade (Infliximab), posted 24/8/2004. Available from URL http://www.fda.gov/medwatch/SAFETY/2004/ safety04.htm#remicade
22. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, TNF neutralization in MS: results of randomized, placebo-controlled , multicenter study. Neurology 1999; 53: 457-65.
23. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002; 359: 540-41.
24. Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet 2001; 358: 1784
25. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319-24.
26. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565-70.
27. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099-100.
28. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-4.
29. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9.
30. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57: 1885-8.
31. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erymematosus associated with etanercept therapy. Lancet 2002; 359:579-80.
32. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist. Ann Intern Med 2003; 138: 807-11.
33. Hamilton CD. Tuberculosis in the Cytokine Era: What Rheumatologists Need to Know. Arthritis Rheum 2003; 48: 2085-91.
34. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44: 1977-83.
35. Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 146-50.
36. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
37. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
38. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
39. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
40. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
41. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-9.
42. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
43. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendung D, Lespessailles E et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 2002; 41: 1280-85.
44. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001; 60: iii55-57.
45. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001; 44: 2933-5.
46. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 1149-54.
47. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295-6.